Calcipotriol

Calcipotriol
Clinical data
Trade names	Daivonex, Dovonex, Sorilux
Other names	calcipotriene (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a608018
License data	US DailyMed: Calcipotriene;
Pregnancy; category	AU: B3; ;
Routes of; administration	Topical administration
ATC code	D05AX02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	5 to 6%
Metabolism	Liver
Excretion	Biliary
Identifiers
	IUPAC name (1R,3S,5E)-5-{2-[(1R,3aS,4Z,7aR)-1-[(2R,3E)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol;
CAS Number	112965-21-6 ;
PubChem CID	5288783;
IUPHAR/BPS	2778;
DrugBank	DB02300 ;
ChemSpider	4450880 ;
UNII	143NQ3779B;
KEGG	D01125 ;
ChEBI	CHEBI:50749 ;
ChEMBL	ChEMBL100918 ;
CompTox Dashboard (EPA)	DTXSID0046648 ;
ECHA InfoCard	100.119.473
Chemical and physical data
Formula	C27H40O3
Molar mass	412.614 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@@H]1CC(\C(=C)[C@@H](O)C1)=C\C=C2/CCC[C@]4([C@H]2CC[C@@H]4[C@@H](/C=C/[C@@H](O)C3CC3)C)C;
	InChI InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1 ; Key:LWQQLNNNIPYSNX-UROSTWAQSA-N ;
	(what is this?) (verify)

Calcipotriol, also known as calcipotriene, is a synthetic derivative of calcitriol, a form of vitamin D. It is used in the treatment of psoriasis.^[1] It is safe for long-term application in psoriatic skin conditions.^{[medical citation needed]}

It was patented in 1985 and approved for medical use in 1991.^[2] It is marketed under the trade name "Dovonex" in the United States, "Daivonex" outside North America, and "Psorcutan" in Germany.^{[citation needed]}

It is on the World Health Organization's List of Essential Medicines.^[3]

Calcipotriol is also available as Calcipotriol/betamethasone dipropionate, a fixed-dose combination medication with the synthetic corticosteroid betamethasone dipropionate for the treatment of plaque psoriasis.^[4]

^ Prendergast B, Harrison J, Kulkarni K, Baguneid M (2016-10-27). Oxford Handbook of Key Clinical Evidence. Oxford University Press. p. 101. ISBN 9780198729426.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 452. ISBN 9783527607495.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^ "Taclonex- calcipotriene and betamethasone dipropionate ointment". DailyMed. 21 May 2020. Retrieved 19 October 2020.

[1] Prendergast B, Harrison J, Kulkarni K, Baguneid M (2016-10-27). Oxford Handbook of Key Clinical Evidence. Oxford University Press. p. 101. ISBN 9780198729426.

[2] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 452. ISBN 9783527607495.

[WHO22nd-3] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[Taclonex_ointment_FDA_label-4] "Taclonex- calcipotriene and betamethasone dipropionate ointment". DailyMed. 21 May 2020. Retrieved 19 October 2020.

[1]

[2]

[3]

[4]